Obstetrics/Gynecology Topics
RSSArticles
-
Nonhormonal Treatment for Menopausal Vasomotor Symptoms: A Phase III Study of Fezolinetant
More than 500 women with moderate to severe menopausal vasomotor symptoms received either 45 mg of fezolinetant, 30 mg fezolinetant, or placebo. Both fezolinetant doses significantly reduced the frequency and severity of menopausal symptoms at four and 12 weeks of treatment vs. placebo.
-
Zuranolone Capsules (Zurzuvae)
Zuranolone can be prescribed to treat postpartum depression.
-
Postpartum Depression Medication Headed to Market
FDA approves first oral solution.
-
Fezolinetant Tablets (Veozah)
Fezolinetant can be prescribed to treat moderate-to-severe vasomotor symptoms caused by menopause.
-
Oral Medication to Treat ‘Hot Flashes’ Could Be Available Soon
The FDA has approved the first neurokinin 3 receptor antagonist to alleviate symptoms associated with moderate to severe vasomotor symptoms caused by menopause.
-
Does Topiramate Decrease the Efficacy of Oral Contraceptives?
Women taking low-dose topiramate (< 200 mg per day) and oral contraception did not experience more contraceptive failures compared to women taking other headache remedies (propranolol, metoprolol, amitriptyline, venlafaxine, or verapamil).
-
Identifying High-Risk Cancer Patients Through Appropriate Screening
Less than 20% of average-risk women receive guideline-adherent cervical cancer screening, and guideline-adherent screening was highest for primary HPV testing.
-
Controlling Blood Pressure During Pregnancy Could Lower Dementia Risk
Investigators found an association between high blood pressure during pregnancy and a higher likelihood of developing dementia later in life.
-
Financial Coaching Boosts Follow-Up Visit, Vaccination Rates for Babies
Assisting low-income new parents can lead to better outcomes.
-
Cumulative Estrogen Exposure Linked to Lower Stroke Risk
These findings could help clinicians sustain their postmenopausal patients’ neurological health.